<SEC-DOCUMENT>0001493152-24-049515.txt : 20250212
<SEC-HEADER>0001493152-24-049515.hdr.sgml : 20250212
<ACCEPTANCE-DATETIME>20241210172204
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER: 0001493152-24-049515
CONFORMED SUBMISSION TYPE: CORRESP
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20241210
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: PowerUp Acquisition Corp.
CENTRAL INDEX KEY: 0001847345
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CORRESP
BUSINESS ADDRESS:
STREET 1: 1200 BROADWAY, FLOOR 3
CITY: NEW YORK
STATE: NY
ZIP: 10038
BUSINESS PHONE: 561-704-8527
MAIL ADDRESS:
STREET 1: 1200 BROADWAY, FLOOR 3
CITY: NEW YORK
STATE: NY
ZIP: 10038
FORMER COMPANY:
FORMER CONFORMED NAME: PowsedrUp Acquisition Corp.
DATE OF NAME CHANGE: 20210222
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aspire BioPharma Inc.
CENTRAL INDEX KEY: 0001995528
ORGANIZATION NAME:
IRS NUMBER: 660991341
STATE OF INCORPORATION: PR
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CORRESP
BUSINESS ADDRESS:
STREET 1: 194 CANDELERO DRIVE
STREET 2: SUITE 223
CITY: HUMACAO
STATE: PR
ZIP: 00791
BUSINESS PHONE: (415)-592-7399
MAIL ADDRESS:
STREET 1: 194 CANDELARO DRIVE
STREET 2: #223
CITY: HUMACAO
STATE: PR
ZIP: 00791
FORMER COMPANY:
FORMER CONFORMED NAME: Aspire BioPharma, Inc.
DATE OF NAME CHANGE: 20230928
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 70%"><IMG SRC="formcorresp_001.jpg" ALT=""></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dykema
Gossett PLLC</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111
E. Kilbourn Ave.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
1050</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milwaukee,
WI 53202</FONT></P>
<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 3pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.dykema.com</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: 414-488-7300</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kate
Bechen</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct
Dial: (414) 488-7333</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
KBechen@dykema.com</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
10, 2024</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Securities and Exchange Commission</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporate Finance</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Office of Life Sciences</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
F Street, N.E.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Tyler Howes, Tim Buchmiller, Eric Atallah, and Lynn Dicker</FONT></P></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PowerUp
Acquisition Corp.</B></FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Amendment
No. 2 to Registration Statement on Form S-4</B></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Filed
November 15, 2024</B></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>File
No. 333-281991</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -27pt"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -27pt"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -27pt"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Mr. Howes, Mr. Buchmiller, Mr. Atallah and Ms. Dicker:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
response letter (this “<B>Response</B>”) is submitted on behalf of PowerUp Acquisition Corp. (the “<B>Company</B>”)
in response to the comments that the Company received from the staff of the Division of Corporation Finance (the “<B>Staff</B>”)
of the U.S. Securities and Exchange Commission (the “<B>SEC</B>”) in a letter addressed to Mr. Ajjarapu, dated December 2,
2024 (the “<B>Comment Letter</B>”), with respect to the Company’s Amendment No. 2 (“<B>Amendment No. 2</B>”)
to its registration statement on Form S-4 (the “<B>Registration Statement</B>”), filed with the SEC on November 15, 2024.
The Company is concurrently submitting a second amendment to the Registration Statement (“<B>Amendment No. 3</B>”), which
reflects the changes discussed in this Response that the Company made to address the Staff’s comments and other updates.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
reference purposes, each of the Staff’s numbered comments from the Comment Letter is set forth in bold text below, followed by
the Company’s response to each comment. All capitalized terms used but not defined in this Response have the meanings ascribed
to them in Amendment No. 3.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
responses below are based on information provided to Dykema Gossett PLLC by the Company.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Amendment
No. 2 to Registration Statement on Form S-4</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Cover
Page</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
note the disclosure you have added to the cover page that “a valuation performed as
part of a third-party fairness opinion estimated the current enterprise value of Aspire to
be approximately $789 million.” However, we note from the disclosure on page 40 that
KPSN’s opinion “only addressed the fairness from a financial point of view to
PowerUp of the shares of New Aspire Common Stock to be issued on the Closing Date as the
consideration in the Business Combination to the Aspire Stockholders and does not address
any other aspect or implication of the Business Combination.” Please either revise
your disclosure throughout the filing to disclose that KPSN also delivered a valuation report
or remove this disclosure from your cover page.</B></FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Response</U>:
</I>In response to the Staff’s comments, the Company has revised its disclosures on the cover page of Amendment No. 3.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">California | Illinois | Michigan
| Minnesota | Texas | Washington, D.C. | Wisconsin</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>
<!-- Field: Page; Sequence: 1 -->
<DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"> </TD></TR></TABLE></DIV>
<DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt"> </P></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Securities and Exchange Commission</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporate Finance</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
10, 2024</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
2</FONT></P></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Summary
of Proxy Statement/Prospectus</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Aspire,
page 36</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
note disclosure stating that you plan to initiate a Phase 1 trial of your Instaprin candidate in March 2025. We also note disclosure
stating that you intend to request a “pre-IND” meeting with the FDA in April 2025. Please revise to clarify if you have filed
an IND application with the FDA for your Instaprin candidate. To the extent you have not, please clearly state that you have not yet
filed an IND application and revise to explain why you will be able to conduct a Phase 1 trial prior to such a submission. If you have
submitted an IND application, please revise to explain the purpose of the contemplated April 2025 meeting with the FDA.</B></FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Response</U>:
</I>In response to the Staff’s comments, the Company has revised its disclosures on page 36 of Amendment No. 3.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
note your disclosure in response to prior comment 5 that Aspire’s dosing of its anticipated
prescription products will follow the standard doses of 82 mg and 325 mg of Aspirin which
you disclose are both available currently over-the-counter. Please clarify if Aspire anticipates
premium pricing for its prescription strength products, if approved, versus the market price
for aspirin that is currently available over-the-counter. Please also revise your disclosure
under the heading “Revenue Assumptions” on page 146 to disclose Aspire’s
assumptions in this regard. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Response</U></I>:
In response to the Staff’s comments, the Company has revised its disclosures on pages 36 and 146 of Amendment No.
3.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Unaudited
Pro Forma Condensed Combined Financial Information</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Adjustments
to Unaudited Pro Forma Condensed Combined Balance Sheet, page 201</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
note your response to comment 14. Your disclosure on page 197 indicates that 1,750,000 shares
of New Aspire Common Stock will be issued as consideration to certain investors for entering
into certain Working Capital Loans. Please tell us why your pro forma presentation reflects
the extinguishment of the Working Capital Loans but does not recognize the issuance of such
loans.</B></FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Response</U>:
</I>In response to the Staff’s comments, the Company has revised its disclosures on pages 197 and 202 of Amendment No.
3. The 1,750,000 shares referenced are attached to the subscription agreements which are currently recognized in the September 30, 2024
Financial Statements.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>
<!-- Field: Page; Sequence: 2 -->
<DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"> </TD></TR></TABLE></DIV>
<DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt"> </P></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Securities and Exchange Commission</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporate Finance</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
10, 2024</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
</FONT>3</P></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Information
about Aspire</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Our
Products, page 215</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
note your response to prior comment 17 and reissue in part. Please revise this section to discuss the endpoints you will assess in your
planned clinical trials of Instaprin.</B></FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Response</U>:
</I>In response to the Staff’s comments, the Company has revised its disclosures on page 215 of Amendment No. 3.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Aspire
Biopharma, Inc. Financial Statements</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Note
7 – Instaprin Acquisition, page F-59</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your
response to comment 22 indicates that you revised your disclosures to clarify and to correct any ambiguity regarding Aspire’s direct
involvement with the SEC. However, your disclosure on pages F-48 and F-59 continues to state that you assumed one liability in the transaction,
which is a contingent liability to the SEC. Please revise to more clearly disclose the extent to which your contingent liability is to
Instaprin Pharmaceuticals, Inc. versus directly negotiated with the SEC.</B></FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Response</U>:
</I>In response to the Staff’s comments, Aspire has revised its disclosure on pages F-48 and F-59 of Amendment No. 3.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
note in response to comment 23 that you performed a more comprehensive fair value assessment
of the intangible assets acquired from Instaprin Pharmaceuticals, Inc. Please address the
following:</B></FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Provide
us with a summary of the more comprehensive fair value assessment you performed. Thoroughly
describe and quantify the methodologies and key inputs and assumptions used to support the
fair value of the intangible assets acquired. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regarding
your Market Participant Perspective valuation, explain how you concluded that a legal settlement
for offering fraud is a level 2 input for determining the fair value of the trade secrets,
patents, proprietary methodologies, commercial and scientist relationships, R&D, trademarks,
and brand equity that you acquired from Instaprin Pharmaceuticals, Inc. Refer to ASC paragraphs
820¬10-35-47 to 51. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revise
your disclosures to provide the gross carrying amount and accumulated amortization for each
major intangible assets class acquired (e.g., trade secrets, patents, proprietary methodologies,
commercial and scientist relationships, etc.). In addition, revise to disclose the weighted-average
amortization period, in total and by each major intangible asset class. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<!-- Field: Page; Sequence: 3 -->
<DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"> </TD></TR></TABLE></DIV>
<DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt"> </P></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Securities and Exchange Commission</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporate Finance</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
10, 2024</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
</FONT>4</P></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
state that you revised the disclosures to reflect the specific factors considered in determining
fair value and to support recoverability and enhanced the disclosures to outline the dates
and specific impairment testing procedures. Tell us specifically where the revised disclosures
are in the September 30, 2024 interim financial statements and the December 31, 2023 annual
financial statements, or revise further as necessary. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Response</U>:
</I>In response to the Staff’s comments, </FONT>Aspire has engaged a firm to perform a comprehensive fair value assessment
and purchase price allocation of the intangible assets acquired. Upon completion of such assessment, Aspire will provide the Staff with
the following:</P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
of the assessment performed which will include a description and will quantify the methodologies and key inputs and assumptions used
to support the fair value of the intangible assets acquired,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
explanation on how management concluded that a legal settlement for offering fraud is a level 2 input for determining the fair value
of the IP acquired,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revised
disclosures to include both carrying amounts and accumulated amortization for each major intangible asset class acquired along with
weighted-average amortization period, in total and by each major intangible asset class, and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revised
disclosure to reflect the specific factors considered in determining fair value and to support recoverability and impairment analysis
and disclosure.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>* * *</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank
you for your review and consideration of the matters set forth in this Response and in Amendment No. 3. If you have any questions, please
contact the undersigned at (414) 488-7333 or KBechen@dykema.com.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 50%"> </TD>
<TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"> </TD>
<TD STYLE="text-align: justify"> </TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dykema Gossett PLLC</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"> </TD>
<TD STYLE="text-align: justify"> </TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><I>/s/ Kate Bechen</I></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"> </TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kate Bechen, Esq.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surendra
Ajjarapu</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PowerUp
Acquisition Corp.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>
<!-- Field: Page; Sequence: 4; Options: Last -->
<DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"> </TD></TR></TABLE></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"> </P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>formcorresp_001.jpg
<TEXT>
begin 644 formcorresp_001.jpg
M_]C_X 02D9)1@ ! 0$ 9 !D #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" !& /H# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]TOVV?VSO
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M4')."#P!DDXY ))P "3@_GW\3_^"IO_ 3P^#'Q!\5_"GXK?M<_!GP+\2/
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M]T\'DDE.NI24;/ZSCE)RCK&?.M??ER_A-_P<%X7_ (+#?MDD]9+K]GUQ[?\
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M>_M-_&6[2".X\6/I.H-H<-U;22V"^(-;O_#7@?PU;Z'X'T.:+PI_ CX^\?\
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M@(".^03^T>!D>Y'MSBOP!_X+6_\ !1K]@3_@I);_ Q^)GP%^$'[0'PX_:2\
M%7[^&O$_BOXC>#?A/H7AOX@_"2ZL[NYBTCQ#?^"OBSXUUV_\3^#/$EOIESX)
MN+C1S9V6B:QXOT^ZN8UNM)^S:\+<4>(689E'*>+>!7A<IQRJTGC:>%MA\'*H
MI1IK'X?$8[%TL3@ZT>?#U:G).<)U(5)X>=.<T8<09!P1EV EC^%^,77S/"RA
M5A@ZN(O4Q3BXW>%JTL%0EA\3"2A4I)R<:D8SIQJ1=.#/ZJ_^"'O_ 5;?_@H
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M\%C:JQ5/*\=3I8*I-N<H8?$8=5?8J4KOV=.<6Z<=%#GG%*UV_P#,5_X."/\
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MC3]H;XF^ _VT?VD_!$^@_LS_ [UG3_%OPM\'>+-.N;>\_:!\=:/+;ZCX5UV
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M]=\3>&]-TWX:>*_"6GO,LFS6O&7B#4/@?H^EVT"RF:>>YNGM_P!S-(W]%O\
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M <&#_C<)^V6>@^T?L^@'MN'[*GP(.,^N"#@<X(..17[Y?\ !I1:6O\ PI+]
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M^-[6[\/Z7>Z6=!\2ZAI?C+P]:1/(;VTU#P/K4MW"MO=:<[_LI_P4W^!>E?\
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MO[$?[ __ 3[_:K_ &AO%OQ&^*WQJ^+O@OX43)X!\0>-O$-MX%\">%_B-KVO
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MHY[>>)VBGAD!26)V1@58BOY3?&/_ :??LH:_P"+?%>M>$_VD/CGX \,:QXB
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M6NV]]+X?\-3:5P_[>'_!OY^P_P#ML>(_$'Q0TBP\0?LX?'3Q-?W>L>(?B/\
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MJ1!4C0*%1$!"HD:*JQHB !%10J(FT <U_-S^US_ ,&VGP,_:[_:9^,?[37B
M7]ICXR>#]?\ C)XIC\4ZGX6T#PK\/[[1=%N(] TG01::==ZII\VH3P(IM
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MNB@M]8^*?AFSM2X N7N;KRV);[+)@*?Z3_^"<?_ 2J_9>_X)K>$=3M?A!I
MNK>+_BIXPL+'3OB/\<_'G]GW7CWQ;;65S]LBT'38M/M;;1_!7@>UU "YL?"7
MANT@2X:TTN]\4ZEXJU[3;;7%**^LS[Q#XQXCP\,MS7.J]7+Y>_4P="EA\)0K
M.$HNFL1'#4X2KTZ<OWD*56I.DJB51TY2C%KYG)^".%\BQ/U[+<KI4<8VZ<<1
M4J5<14IPFI2G[%UY3C1E/X95*<8U'#W%.,=_T^HHHKY ^I"BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>